BACKGROUND: With prolonged replication, attenuated polioviruses used in oral polio vaccine (OPV) can mutate into vaccine-derived poliovirus (VDPV) and cause poliomyelitis outbreaks. Individuals with primary humoral immunodeficiencies can become chronically infected with vaccine poliovirus, allowing it to mutate into immunodeficiency-associated VDPV (iVDPV). It is unclear if children perinatally infected with the human immunodeficiency virus (HIV), who have humoral as well as cellular immunodeficiencies, might be sources of iVDPV. METHODS: We conducted a prospective study collecting stool and blood samples at multiple time points from Zimbabwean infants receiving OPV according to the national schedule. Nucleic acid extracted from stool was analyzed by real-time polymerase chain reaction for OPV serotypes. RESULTS: We analyzed 825 stool samples: 285 samples from 92 HIV-infected children and 540 from 251 HIV-uninfected children. Poliovirus shedding was similar after 0-2 OPV doses but significantly higher in the HIV-infected versus uninfected children after ≥ 3 OPV doses, particularly within 42 days of an OPV dose, independent of seroconversion status. HIV infection was not associated with prolonged or persistent poliovirus shedding. HIV infection was associated with significantly lower polio seroconversion rates. CONCLUSIONS: HIV infection is associated with decreased mucosal and humoral immune responses to OPV but not the prolonged viral shedding required to form iVDPV.
BACKGROUND: With prolonged replication, attenuated polioviruses used in oral polio vaccine (OPV) can mutate into vaccine-derived poliovirus (VDPV) and cause poliomyelitis outbreaks. Individuals with primary humoral immunodeficiencies can become chronically infected with vaccine poliovirus, allowing it to mutate into immunodeficiency-associated VDPV (iVDPV). It is unclear if children perinatally infected with the human immunodeficiency virus (HIV), who have humoral as well as cellular immunodeficiencies, might be sources of iVDPV. METHODS: We conducted a prospective study collecting stool and blood samples at multiple time points from Zimbabwean infants receiving OPV according to the national schedule. Nucleic acid extracted from stool was analyzed by real-time polymerase chain reaction for OPV serotypes. RESULTS: We analyzed 825 stool samples: 285 samples from 92 HIV-infectedchildren and 540 from 251 HIV-uninfectedchildren. Poliovirus shedding was similar after 0-2 OPV doses but significantly higher in the HIV-infected versus uninfectedchildren after ≥ 3 OPV doses, particularly within 42 days of an OPV dose, independent of seroconversion status. HIV infection was not associated with prolonged or persistent poliovirus shedding. HIV infection was associated with significantly lower polio seroconversion rates. CONCLUSIONS:HIV infection is associated with decreased mucosal and humoral immune responses to OPV but not the prolonged viral shedding required to form iVDPV.
Authors: Olen M Kew; Roland W Sutter; Esther M de Gourville; Walter R Dowdle; Mark A Pallansch Journal: Annu Rev Microbiol Date: 2005 Impact factor: 15.500
Authors: Dobromir N Pavlov; Walda B Van Zyl; Mariane Kruger; Liezl Blignaut; Willie O K Grabow; Marthie M Ehlers Journal: Diagn Microbiol Infect Dis Date: 2005-11-14 Impact factor: 2.803
Authors: W T Shearer; K A Easley; J Goldfarb; H M Rosenblatt; H B Jenson; A Kovacs; K McIntosh Journal: J Allergy Clin Immunol Date: 2000-09 Impact factor: 10.793
Authors: D N Pavlov; W B Van Zyl; J Van Heerden; M Kruger; L Blignaut; W O K Grabow; M M Ehlers Journal: J Appl Microbiol Date: 2006-12 Impact factor: 3.772
Authors: Nino Khetsuriani; Rita Helfand; Mark Pallansch; Olen Kew; Ashley Fowlkes; M Steven Oberste; Peter Tukei; Joseph Muli; Ernest Makokha; Howard Gary Journal: BMC Infect Dis Date: 2009-08-23 Impact factor: 3.090
Authors: Louise C Ivers; Richelle C Charles; Isabelle J Hilaire; Leslie M Mayo-Smith; Jessica E Teng; J Gregory Jerome; Jenna Rychert; Regina C LaRocque; Peng Xu; Pavol Kovácˇ; Edward T Ryan; Firdausi Qadri; Charles P Almazor; Molly F Franke; Jason B Harris Journal: J Infect Dis Date: 2015-02-26 Impact factor: 5.226
Authors: James A Church; Sandra Rukobo; Margaret Govha; Marya P Carmolli; Sean A Diehl; Bernard Chasekwa; Robert Ntozini; Kuda Mutasa; Jean H Humphrey; Beth D Kirkpatrick; Andrew J Prendergast Journal: Hum Vaccin Immunother Date: 2017-08-31 Impact factor: 3.452
Authors: Joanne Hassan; Laura Wangai; Peter Borus; Christopher Khayeka-Wandabwa; Lucy Wanja Karani; Mercy Kithinji; Michael Kiptoo Journal: BMC Res Notes Date: 2017-11-03